Gene therapy gel aims to stop skin cancer from coming back in RDEB patients
NCT ID NCT06731933
First seen Apr 26, 2026 · Last updated Jun 19, 2026 · Updated 9 times
Summary
This phase 2 trial tests whether a gene therapy gel called BVEC can reduce the return of squamous cell carcinoma (a type of skin cancer) in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that causes fragile, blistering skin. The gel is applied to the skin after cancer removal to try to normalize the tissue and prevent recurrence. The study involves 16 adults in the US and Italy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedliero-Universitaia
RECRUITINGBari, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University
RECRUITINGRedwood City, California, 94063, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Beremagene geperpavec (BVEC) - a gene therapy gel applied to the skin
What this could lead to
If it works, this could reduce the chance of skin cancer coming back after surgery in people with RDEB, potentially extending their lives.
What could go wrong
This is a small early-phase trial with only 16 people, so results may not apply to everyone. The gel is only tested on specific skin spots, and it may not prevent new cancers elsewhere.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.